Comparative Cost-Effectiveness of Advanced Treatment Sequences for Moderately to Severely Active Ulcerative Colitis in Japan. (PubMed, Adv Ther) - Sep 9, 2026 - "Under the assumptions of this model, a treatment sequence with first-line etrasimod followed by second-line upadacitinib was identified as the most cost-effective strategy for advanced therapy-naïve patients with moderately to severely active UC in Japan."
HEOR • Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis
|
|
Akira Yuasa; Ernest H Law; Hiroyuki Matsuda; Katsuya Yamagami; Kazumasa Kamei; Masato Hoshi; Miwa Enami; Yawen Dai
|